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Abstract
Objective: Cross-sectional data show that post-traumatic stress disorder (PTSD) patients often
have increased levels of circulating inflammatory markers. There is, however, still a paucity of
longitudinal studies with long follow-up times on levels of cytokines in such patients. The cur-
rent study assesses patients with and without PTSD diagnosis 1 year after discharge from
inpatient treatment.Methods: Patients in treatment for serious non-psychotic mental disorders
were recruited at the beginning of their treatment stay at a psychiatric centre in Norway. Ninety
patients submitted serum samples and filled out the Hopkins Symptom Checklist-90 Revised
Global Severity Index (HSCL-90R GSI) questionnaire during their mainstay and at a follow-up
stay 1 year after discharge. Of these patients, 33 were diagnosed with PTSD, 48 with anxiety,
depression, or eating disorder, while 9 patients had missing data. The patients were diagnosed
using theMini-International Neuropsychiatric Interview (MINI). Results:At the follow-up stay
(T3), PTSD patients had higher levels of GSI scores than non-PTSD patients (p = 0.048).
These levels were unchanged from the year before (T2) in both groups. The levels of circu-
lating cytokines/chemokine did not differ between the PTSD and non-PTSD patients at T3.
At T2, however, the PTSD and non-PTSD groups exhibited different levels of interleukin 1β
(IL-1β) (p = 0.053), IL-1RA (p = 0.042), and TNF-α (p = 0.037), with the PTSD patients
having the higher levels. Conclusion: Despite exhibiting different mental distress scores,
the PTSD and non-PTSD patients did not differ regarding levels of circulating inflamma-
tory markers at 1-year follow-up.
Significant outcome
PTSD and non-PTSD patients showed persistently different scores of mental distress 1 year
after psychiatric treatment. In contrast, their cytokine levels did not differ 1 year after dis-
charge from a psychiatric treatment inpatient stay.
Limitations
The patients with higher scores of mental distress were those who attended the follow-up
stay, introducing a selection bias to the study. Further, it was not assessed whether the
patients were fasting or smoking cigarettes prior to blood collection, or their sleeping or
physical exercise status.
Introduction
The notion of inflammation as a cause, consequence, or correlate in psychiatric diseases has
been extensively investigated in recent decades (Reus et al., 2015). Studies of inflammatory
markers have provided evidence of elevated levels of interleukin-6 (IL-6), interleukin 1β (IL-
1β), and interferon-γ (IFN-γ) in people diagnosed with post-traumatic stress disorder
(PTSD) (Gill et al., 2009; Passos et al., 2015). However, PTSD has largely been investigated
in cross-sectional studies (Sumner et al., 2020), not providing insight into the development
of inflammatory markers over time. Furthermore, the body of evidence is still mixed
(Michopoulos et al., 2017; Toft et al., 2018a; Lima et al., 2019; Sumner et al., 2020).
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Trauma is a prerequisite of PTSD, but other parts of its aetiol-
ogy remain largely unknown (Hori et al., 2019). The investigation
of certain inflammatory biomarkers commonly related to PTSD
may enhance understanding of the role that biological factors play
in PTSD (Hussein et al., 2017). It has been suggested that an altered
inflammatory marker profile is a risk factor for developing PTSD
(Michopoulos et al., 2019; Sumner et al., 2020). Also, higher levels
of IL-6 and IL-8 have been associated with higher symptoms of
acute stress and post-traumatic stress symptoms (Cohen
et al., 2011).
Inflammation in PTSD has previously been investigated in
adult individuals who experienced childhood maltreatment
(Wieck et al., 2014; Koenig et al., 2018), in patients with war-
related trauma (Lindqvist et al., 2017), and in patients admitted
to emergency wards immediately after trauma exposure
(Michopoulos et al., 2019). There is still a gap in the literature
on longitudinal studies of cytokines in psychiatric patients. This
study recruited psychiatric patients who participated in an
inpatient, intensive treatment programme lasting 12 weeks.
Their suffering had persisted over time, and previous treatment
efforts were insufficient to achieve recovery. The current study
included patients who attended a 5-day follow-up stay 1 year after
treatment termination. Thus, this study design that includes mea-
surement points at admission, at mid-treatment, at discharge, and
at 1-year follow-up enables us to contribute to the long-running
debate on whether cytokines are trait or state markers in patients
and whether there are cross-diagnostic differences. We have pre-
viously found the cytokines IL-1β, TNF-α, IL-1RA, and the chemo-
kine MCP-1 to be elevated in inpatients with PTSD when
compared to patients without PTSD (Toft et al., 2018a). This
was, however, observed over a period of only 12 weeks. In the
present study, we aimed to explore the cytokine levels and psycho-
metric scores in patients with and without PTSD at 1-year follow-
up. Accordingly, our research question was whether cytokine levels
and mental distress in patients with and without PTSD would be
similar or different 1 year later.
Material and methods
Study participants and recruitment procedure
Patients were recruited from the Modum Bad Psychiatric Center, a
specialised psychiatric treatment centre for adults in Norway,
offering treatment to patients with long-standing or treatment-
resistant trauma, anxiety, or eating and depressive disorders.
Patients who are currently using illegal substances or are alcohol
dependent are not eligible for treatment at the centre and are
referred elsewhere. The facility offers group and individual thera-
pies in a 12-week inpatient treatment programme. The patients
were admitted in groups of eight at a time. The patients were given
a 15-minute presentation of the study during group therapy by the
first author during the first days of their stay. Written information
was handed out, explaining the aim of the study and the procedures
involved. A consent form was also distributed to each potential
participant. Data from the mainstay were collected from March
2015 to April 2016, while the follow-up measurements took place
approximately 1 year after discharge from the mainstay. There
were some minor differences in the precise number of months
from discharge to 1-year follow-up [mean 14.5 months, standard
deviation (SD) 1.5]. In total, 90 (61.2%) of the 147 patients who
consented to participate in the study during their mainstay partici-
pated at the follow-up measurement. Of these 90 patients, there
were 24 men (mean age 48, SD 8.4), while 66 were women (mean
age 38, SD 10.3). The genders differed significantly in age (t= 2.11,
p=< 0.001). Of the 57 patients who did not attend the follow-up
stay, there were 18 men (mean age 48, SD 10.9) and 39 women
(mean age 41, SD 13.3). Again, there was a significant age differ-
ence between genders (t= 4.34, p= 0.04). When comparing those
who attended follow-up with those who did not, the 90 attendees
had a mean age of 41 years (SD 10.8), while the 57 non-attendees
had amean age of 43 years (SD 13.0). There was thus no significant
age difference between attendees and non-attendees at the follow-
up stay (p= 0.326). There were nine patients who hadmissing data
on diagnosis, and these were excluded from the statistical analyses.
As part of clinical interviewing, the patient’s trauma history was
assessed by the therapists at the clinic. The clinic used five ques-
tions developed on-site to assess the degree of trauma exposure.
The first three questions assess childhood trauma, while the last
two assess adulthood trauma. In the current paper, having experi-
enced any of these kinds of trauma at all was recorded as having
trauma experience. The questions were as follows: (1) Has the
patient been exposed to sexual assaults in childhood? (2) Has
the patient been exposed to physical abuse in childhood? (3)
Has the patient experienced other traumatic childhood events,
which led to serious problems later? (4) Has the patient been
exposed to sexual assaults or abuse in adulthood (after 18 years
of age)? (5) Has the patient experienced other traumatic events
in adulthood, which led to serious problems later?
All patients were interviewed by trained psychologists or psy-
chiatrists using the Mini-International Neuropsychiatric
Interview (MINI) (Sheehan et al., 1998). The MINI interview pro-
vides information to be used when assessing diagnoses in the 10th
revision of the International Classification of Diseases and Related
Health Problems (ICD-10). Other helpful information for staff
assessment of patients’ disorders included a combination of several
psychometric questionnaires, interviews, and clinical judgement.
All disorders were in the areas of depression, anxiety, and eating
disorders. The ICD-10 diagnosis F43.1 PTSD is a chronic condi-
tion that develops in response to extreme stressors like military
combat, sexual, or physical abuse in childhood or adulthood, natu-
ral disasters, or similar catastrophic events (Foa & Yadin, 2011). In
order to diagnose PTSD, the symptomsmust have been present for
more than 1 month (Grinage, 2003).
The Hopkins Symptom Checklist-90 Revised (HSCL-90R)
questionnaire was administered to assess the patients’ mental dis-
tress (Derogatis et al., 1973). Patients completed the HSCL-90R
self-report questionnaire either on a computer or on a digital tablet.
The HSCL-90R is a 90-item questionnaire measuring the levels of
psychological distress during the past 7 days. A mean score, the
Global Severity Index (GSI), is calculated from all items, each
ranging from 0 to 4. The questionnaire assesses symptoms of
somatisation, obsession, and compulsion, depression, anxiety,
and hostility. The GSI is an overall scale taking various symptoms
into account, thus tapping into symptoms common to a hetero-
geneous psychiatric patient sample (Rytila-Manninen et al.,
2016). The HSCL-90R has been shown to provide a psychomet-
rically valid evaluation of psychiatric patients regarding the
severity of depression, specific anxiety, and interpersonal sensi-
tivity (Bech et al., 2014). A cut-off for caseness was set at a
GSI score of 0.85 (Pedersen & Karterud, 2004). The HSCL-90R
questionnaires were submitted within 1 week of entering treat-
ment (T0), at the halfway stage (T1), and a few days before
discharge (T2). Patients were also followed up approximately
1 year after discharge from their mainstay (T3).
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Blood collection and serum preparation
The blood samples were drawn at T0, T1, T2, and T3. They were
collected between 08 : 00 am and 09 : 00 am, except for 16 patients
from the depression ward, who had their blood drawn between
12 : 00 am and 03 : 00 pm. Patients sat in an upright position when
blood was collected. Vacuette 8ml serum containers were used for
blood collection. These were turned upside-down 8–10 times
immediately after the blood was collected, and allowed to clot
for 30–60 min. The samples were then spun at 1917 g for 10 min
at room temperature. Separated serum samples were put to freeze
at −80°C until assay.
Cytokine and chemokine measurements
We analysed seven cytokines and one chemokine based on the
available literature on the neuroimmune correlates of psychiatric
disorders: IL-1β, IL-1RA, IL-6, IL-10, IL-17A, IFN-y, MCP-1,
and TNF-α. The unit of measurement was picograms per millilitre
(pg/ml). Four cytokines had too many values under the limit of
detection (LOD) (> 55%) and were excluded from the study.
The following cytokines were taken into consideration: IL-1β,
IL-IRA, MCP-1, and TNF-α. Serum samples were thawed on
ice, vortexed, and then spun down a tube with 250 μl serum at
14 000 g for 10 min at 4°C, before dilution (1 : 5) and further
processing. The cytokine measurements were performed using
Bio-Plex xMAP Technology (Bio-Rad, Austin, TX, USA) with a
Luminex IS 100 instrument (Bio-Rad, Hercules, CA, USA), pow-
ered using Bio-Plex Manager (version 6.0.1) software. The assay
was performed according to the manufacturer’s instructions,
but an additional standard point was included. To achieve a more
reliable result, individual sets of samples from patients were run in
the same assay, all samples were assayed in duplicate, and a mag-
netic plate washer was used during assay set up. The StatLIA soft-
ware package (version 3.2; Brendan Scientific, Carlsbad, CA, USA)
incorporates a weighted, five-parameter logistic curve-fitting
method and was used to calculate sample cytokine concentrations.
Longitudinal controls were used in order to validate inter-assay
variation: IL-1β (18.1%), IL-1RA (10.2%), MCP-1 (6.7%), and
TNF-α (7.4%). The inter-assay percentage of variability (CV) in
parentheses is a measure of variation between plates, where a lower
figure is better. Any figure below 21% is considered acceptable. The
mean inter-assay percentage CV for all blood sample plates was
10.4%. An inter-assay percentage CV of 10–12% is common.
The blood samples from the follow-up stay (T3) were analysed
in a separate batch by the same laboratory as the first three mea-
surements. These samples were analysed in 2018. The same proce-
dures as described for the first batch were applied. The inter-assay
percentage CVs were IL-1β (12.3%), IL-1RA (8.6%), MCP-1
(7.8%), TNF-α (8.1%). The mean inter-assay percentage CV for
all blood sample plates was 11.4%.
Limit of detection and imputation
The values below the LODwere replaced with the LOD values (val-
ues in pg/ml). The amounts of zero values and the LOD varied
across each of the four measurements. For IL-1β at T0 and T1, there
were 44 zero values at each measurement point (48.9% and 49.4%
imputations, respectively) and the LODwas 0.01. At T2, there were
42 zero values (47.7%) and the LOD was 0.02. At T3, there were 62
zero values (69.7%) and the LOD was 0.01. For IL-1RA at T0, there
was 1 zero value (0.01%) and the LODwas 7.87. There were no zero
values for IL-1RA at T1 and T2. For IL-1RA at T3, there were 8 zero
values (9.9%) and the LOD was 20.01. For MCP-1 at T0, there were
5 zero values (5.7%) and the LODwas 0.76. At T1, there were 4 zero
values (4.44 %) and the LOD was 1.72. At T2, there were 5 zero
values (5.6%) and the LOD was 1.55. At T3, there were no zero val-
ues. For TNF-α at T0, there were 37 zero values (41.1%) and the
LOD was 0.02. At T1, there were 29 zero values (32.6%) and
the LOD was 0.03. At T2, there were 31 zero values (35.2%) and
the LOD was 0.02. All patients showed up for blood sampling at
T0. There was 1 patient who did not show up for blood sampling
at T1, 2 patients who did not show up at T2, and 1 patient who did
not show up for the blood sampling at T3. These patients still par-
ticipated by submitting their HSCL-90R GSI scores. At T0, all
patients successfully submitted their GSI scores, but at T1, data
were missing for 6 patients. At T2 and T3, data were missing for
13 patients. The study was approved by the Norwegian Regional
Ethics Committee prior to data collection (reference number
2014/2189).
Statistical analyses
The Shapiro–Wilk test was used to test for normal distribution in
all variables. The HSCL-90R GSI scores were normally distributed
at T0 (p= 0.213) and T1 (p= 0.104). Age was also normally distrib-
uted (p= 0.287). All other variables were not normally distributed.
To maintain parsimony, the non-parametric Mann–Whitney U-test
was employed to assess differences between PTSD and non-PTSD
patients for all variables. Pearson’s chi-square test was used to
assess differences between categorical variables. Fisher’s exact test
was used for analysing categorical variables with fewer than five
observations. Logistic multilevel regression models were used to
assess possible interaction effects between time-varying cytokines/
chemokine and GSI scores on PTSD as a binary-dependent variable.
The advantage of multilevel models is that they handle the depend-
ency of measurements within each patient, thus constituting a two-
level structure (Sommet & Morselli, 2017). All statistical analyses
were conducted with Stata (StataCorp. 2019, Stata Statistical
Software: Release 16, College Station, TX, USA: StataCorp LLC).
Results
Table 1 presents means and frequencies of gender, age, trauma his-
tory, mental distress, as well as mood, anxiety, and eating disorders
stratified by PTSDdiagnosis. Figure 1 ( A–E) shows themean levels
at T0–T3 for cytokines/chemokine and GSI, thus graphically pre-
senting the levels and development across time. The PTSD patients
had significantly higher GSI levels than non-PTSD patients at the
follow-up stay (T3) (p= 0.048). This difference was also seen at T0
(p= 0.014) and T2 (p= 0.050). The cytokines/chemokine did not
differ significantly between the PTSD and non-PTSD group at T3.
In contrast, the groups exhibited different levels (trend to signifi-
cance) of IL-1β (p= 0.053), IL-1RA (p= 0.042), and TNF-α at T2
(p= 0.037), with the PTSDpatients having the higher levels. In addi-
tion, longitudinal multilevel logistic regression models were
employed to test the possible interaction effects between cyto-
kines/chemokine and GSI scores on the association with having
PTSD comparedwith not having PTSD. Thesemodelswere run sep-
arately for each cytokine/chemokine and adjusted for age and sex.
There were no significant interactions (data are not shown).
Discussion
In this 1-year post-discharge follow-up study, PTSD patients con-
tinued to report significantly higher levels of mental distress than
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non-PTSD patients. This difference was not reflected in the levels
of some commonly measured cytokines, where we observed more
similar levels at the 1-year follow-up. The GSI scores in both
patient groups remained high, indicating that a severe but
unchanging psychiatric state could be associated with escalating
levels of IL-1RA, MCP-1, and TNF-α, regardless of diagnosis.
Put differently, the levels of the cytokine/chemokines are not nec-
essarily reflected in the psychiatric symptom scores. This is some-
what in line with our previous study that found decreasing GSI
scores, but increasing cytokine levels in PTSD patients (Toft et al.,
2018b). The unchanged mental distress since discharge from the
mainstay may indicate that the effect of the treatment is beyond
the treatment period, at least in this particular patient sample.
Moreover, the declining levels of IL-1β in PTSD patients suggest
that these patients have an inflammatory response that does not
entirely follow the pattern of patients without PTSD, again under-
scoring the distinct neuroimmune features of PTSD patients, at
least for cytokine IL-1β. This finding is not in line with the expect-
ation that levels of IL-1β and IL-1RA would generally follow each
other, as IL-1RA acts as an antagonist and is secreted in response to
increasing levels of IL-1β (Gabay et al., 2010).
Hypoactivity of the hypothalamic–pituitary–adrenal axis, along
with the hyperactive sympathetic nervous system, is considered a
trademark of PTSD (Hori & Kim, 2019). PTSD patients usually
exhibit decreased secretion of cortisol, as well as having glucocor-
ticoid receptors (GRs) more sensitive to cortisol, altogether render-
ing the individual vulnerable to suffering from an abnormal
immune response (Hori & Kim, 2019). This could reflect their high
scores in mental distress, which might be explained by a blunted
cortisol feedback system in response to stressors, or possibly a
habituation to repeated exposures to stressors in individuals diag-
nosed with PTSD (Michopoulos et al., 2019). The similar cytokine
levels of PTSD and non-PTSD patients at the follow-up stay could
be explained by enhancedGR sensitivity and reduced cortisol levels
in both patient groups (Hori & Kim, 2019). These are features of
PTSD patients that distinguish them from patients with major
depression disorder (MDD), as MDD patients are reported to
exhibit hypercortisolism in addition to reduced GR sensitivity.
Both groups shared a history of trauma, and thus did not differ
greatly in this regard. The trauma experience might be the neces-
sary prerequisite for suppressed cortisol levels and increasing cyto-
kines as a consequence (Hori & Kim, 2019), suggesting that the
type of diagnosis is not as relevant as the trauma experience in
itself. This provides a rationale for why we see increased IL-
1RA, MCP-1, and TNF-α in both PTSD and non-PTSD groups
in the current study.
In our previous papers (Toft et al., 2018a; Toft et al., 2018b; Toft
et al., 2020), PTSD patients exhibited escalating cytokine responses
in comparison to patients without PTSD who were diagnosed with
MDD, anxiety disorders, and eating disorders. The lack of
differences at follow-up could indicate that at 1 year, the patients’
immune system had either adapted to a more normalised state, or
that both groups exhibited abnormal levels regardless of diagnosis.
This finding is in line with a prospective study on PTSD patients
which found levels of TNF-α to differ from those of healthy con-
trols at the first measurement, but did not find any difference at
the second measurement 5 years later (Vidovic et al., 2009).
Despite differences in follow-up time and different control groups,
the results are in line with the results from other studies (Vidovic
et al., 2009).
When considering the findings of no differences in IL-1β in the
current paper together with previous findings of higher IL-1β levels
in PTSD patients during the mainstay (Toft et al., 2018a), the
results appear to point in different directions. Finding conflicting
results is in line with results reported in a 2018 systematic review
on IL-1β in PTSD patients (Waheed et al., 2018). The authors sug-
gested that it is premature to consider IL-1β as a biomarker of
PTSD, as the results when comparing levels of IL-1β in PTSD
patients and controls were mixed. Moreover, the review assessed
two longitudinal studies on IL-1β in PTSD, both of which lent
some support to findings in the current study. IL-1β was not
detectable in a proportion of participants at both time points
Table 1. Patient characteristics at 1-year follow-up
Variable
No PTSD PTSD
P-valuen (%) 48 (59.3) 33 (40.7)
Age (years) mean (SD) 39.6 (10.9) 41.9 (10.6) 0.398*
Women N (%) 35 (72.9) 25 (75.8) 0.984†
Trauma history
No N (%) 18 (37.5) 0 (0.0) <0.001†
Yes N (%) 30 (62.5) 33 (100.0)
HSCL-90R GSI‡
T0 mean (SD) 1.44 (0.6) 1.79 (0.67) 0.014*
T1 mean (SD) 1.32 (0.6) 1.53 (0.7) 0.212
T2 mean (SD) 1.17 (0.7) 1.52 (0.7) 0.050
T3 mean (SD) 1.11 (0.7) 1.49 (0.6) 0.048
Mood disorders N (%) 20 (41.7) 3 (9.1) <0.001†
Anxiety disorders N (%) 6 (18.2) 27 (81.8) <0.001
Eating disorders N (%) 15 (31.3) 4 (12.1) 0.046
*Mann–Whitney U-test.
†Pearson’s chi-square. Fisher’s exact test when fewer than five observations. ‡HSCL-90R GSI= Hopkins Symptom Checklist-90 Revised Global Severity Index.
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(Jergovic et al., 2015), not unlike the current study, which had
approximately 50% imputation of IL-1β. Furthermore, IL-1β
increased during the first 3 months (Jergovic et al., 2015), which
was similar to our findings from the mainstay. The other longi-
tudinal study found the levels of IL-1β to decrease in both
PTSD and controls in a double-blind, randomised controlled trial
(Tucker et al., 2004). This partly agrees with the findings in the
current study, where PTSD patients had lower levels than the year
before.
This study has limitations and strengths. It is a strength that
we had four measurements, as the cytokines exhibited a non-
linear pattern from the mainstay to the follow-up stay. This
indicates the necessity of analysing cytokines across a long
period of time, as the associations follow somewhat unexpected
patterns.
It is a limitation that the patients who chose to come back 1 year
later and complete the follow-up treatment had considerably (but
not significantly) higher distress measured by GSI than those who
only participated at the mainstay. This was found in preliminary
analyses of GSI scores at T2 between those who did and did not
participate at follow-up (data are not shown), although the differ-
ence was not significant. This represents a selection bias that could
explain why all cytokines, apart from IL-1β, were higher at the
follow-up stay. Having been away from treatment for 1 year could
have resulted in a more excessive inflammatory state at follow-up,
although not reflected in GSI scores, than if all 147 patients had
been included.
Furthermore, the follow-up measurement was analysed 2 years
later than the first three measurements, although by the same lab-
oratory personnel and in the same laboratory. Different batches are
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Fig. 1. Development of symptoms of mental
distress (A) and inflammatory markers (B–E)
at psychiatric inpatient treatment and at 1-year
follow-up stay. (A) Depicts the measurements
(means, SD) of mental distress measured by
the Hopkins Symptom Checklist-90 Revised
Global Severity Index (HSCL-90R GSI) question-
naire. The inflammatory markers (B–E) were
analysed in serum blood samples, which were
collected during the first week of the treatment,
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prone to give different results, leaving the results between the two
blood sample batches susceptible to measurement differences.
Further, we did not record whether patients were fasting prior
to blood collection. We did not assess body mass index, whether
they were smokers, or if the patients had been physically active
prior to blood collection. These are all factors known to influence
cytokine production (Rubin et al., 2008; Belchamber et al., 2014;
Rivera et al., 2017; Sieske et al., 2019). In addition, there was a
rather high amount of zero values in cytokine IL-1β, and no firm
conclusions should be made about this cytokine against this
background.
In conclusion, this study suggests that having a PTSD diagnosis
or not is unrelated to inflammatory levels 1 year after psychiatric
treatment. Despite exhibiting different cytokine levels and trajec-
tories at the mainstay, these differences between PTSD and non-
PTSD patients were eliminated 1 year later.
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